WELLlife™ COVID-19/Influenza A&B Test

	INTENDED USE: For in vitro rapid, simultaneous qualitative detection and differentiation of influenza A and influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen directly from anterior nasal swab specimens within the first five (5) days of symptom onset
	ACCURACY: SARS-CoV-2 : PPA 87.5%, NPA 99.7%, Flu A : PPA 85.9%, NPA 99.7%, Flu B : PPA 86.8%, NPA 99.7%
	CPT code: 87811QW (COVID-19), 87804QW (Flu A), 87804QW-59 (Flu B)
	Shelf life: 6 months
	Storage conditions: 2-30°C/36-86°F

* In the USA, this product has not been FDA cleared or approved, but has been authorized by FDA under an Emergency Use Authorization. This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A, and influenza B, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/ or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

WELLlife™ COVID-19 and Influenza A&B Test

Contact Us For Customized Pricing and Expert Support

For Emergency Use Authorization (EUA) Only* | For in vitro diagnostic use

Why Choose WELLlife COVID-19/Influenza A&B Test:

Product Specifications

Test Procedure

Ordering Information

	COST-EFFECTIVE CLARITY: Differentiate between 3 antigens with just 1 swab, saving both time and resources
	RAPID RESULTS: Empowered in only 10 minutes to make informed treatment decisions
	UNMATCHED QUALITY ASSURANCE: Outstanding clinical performance, incl. external controls set for quality testing

	PATIENT FRIENDLY: Painless shallow nasal swab sample collection
	QUICK 3-STEP TEST PROTOCOL: Simplifies product management and accessibility
	EXTENDED DETECTION WINDOW: Differentiation possible within 5 days of symptom onset